Source: Eur Respir J 2013; 42: 616-625
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Afroditi K. Boutou, Dinesh Shrikrishna, Rebecca J. Tanner, Cayley Smith, Julia L. Kelly, Simon P. Ward, Michael I. Polkey, Nicholas S. Hopkinson. Lung function indices for predicting mortality in COPD. Eur Respir J 2013; 42: 616-625

Member's Comments

No comment yet.

Related content which might interest you: Use of tiotropium Respimat Soft Mist Inhaler versus HandiHaler and mortality in patients with COPD Source: Eur Respir J 2013; 42: 606-615 Year: 2013 A trial of beclomethasone/formoterol in COPD using EXACT-PRO to measure exacerbations Source: Eur Respir J 2013; 41: 12-17 Year: 2013 Efficacy of tiotropium Respimat® in adults with moderate asthma, by baseline LTRA use Source: International Congress 2015 – Modulating the immune system in COPD and asthma Year: 2015 Modelling the 5-year cost-effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease (COPD) in Spain Source: Eur Respir J 2006; 28: Suppl. 50, 683s Year: 2006 Hemodynamic effects of inhaled fenoterol and ipratropium in patients with obstructive pulmonary diseases Source: International Congress 2014 – Monitoring airway diseases with lung function tests Year: 2014 Tiotropium in COPD patients Source: Breathe 2008; 5: 271 Year: 2009 Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 Safety of once-daily tiotropium and olodaterol fixed-dose combination via the respimat in chronic obstructive pulmonary disease in two 1-year studies Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Effect of tiotropium compared to salmetrol on dynamic hyperinflation in patients with chronic obstructive pulmonary disease Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 Tiotropium + olodaterol in patients with moderate to severe COPD with chronic bronchitis and/or emphysema Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Once-daily glycopyrronium improves lung function and reduces exacerbations in severe-to-very severe COPD patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 Efficacy of tiotropium and indacaterol alone or the combination on dynamic lung hyperinflation and exercise tolerance in COPD Source: International Congress 2014 – Asthma and COPD management Year: 2014 Use of tiotropium Respimat versus HandiHaler and mortality in patients with COPD Source: Eur Respir J 2014; 43: 1818-1819 Year: 2014 Use of tiotropium Respimat versus HandiHaler and mortality in patients with COPD Source: Eur Respir J 2014; 43: 1816-1818 Year: 2014 Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Prevention of deteriorations in COPD on stepping up from tiotropium to umeclidinium/vilanterol Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Preference, satisfaction and critical errors with Genuair® and Breezhaler® in patients with COPD Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 First dose response to tiotropium in COPD: Impact on dyspnea, lung hyperinflation and distal airways Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013 COPD and asthma patients are satisfied with handling and inhalation characteristics of Soft Mist InhalerÔ (Berodual® Respimat®) Source: Eur Respir J 2006; 28: Suppl. 50, 739s Year: 2006